Welcome to our dedicated page for Park Ha Biological Technology Co., Ltd. SEC filings (Ticker: PHH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Park Ha Biological Technology Co., Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Park Ha Biological Technology Co., Ltd.'s regulatory disclosures and financial reporting.
Park Ha Biological Technology Co., Ltd. announced a change of trading symbol for its ordinary shares to BYAH, from PHH. The Company anticipates the new ticker will become effective on the Nasdaq Stock Market at the open of trading on Monday, October 28, 2025.
The Company also issued a press release about the ticker symbol change, furnished as Exhibit 99.1.
Park Ha Biological Technology Co., Ltd. reports that shareholders approved several major corporate actions at the 2025 annual general meeting. Holders of 21,872,753 ordinary shares, out of 33,874,403 issued and outstanding as of the September 8, 2025 record date, voted, satisfying quorum requirements.
Shareholders approved a redesignation of the company’s capital so it is authorized to issue 15,000,000,000 ordinary shares of par value US$0.00002 each, split into 12,000,000,000 Class A shares with 1 vote per share and 3,000,000,000 Class B shares with 20 votes per share. The existing 33,874,403 ordinary shares were reclassified as Class A, and 19,050,000 Class A shares held by Xiaoqiu Zhang will be surrendered for nil consideration in exchange for 19,050,000 Class B shares.
Shareholders also approved new amended and restated constitutional documents to reflect the dual-class structure and streamline meeting requirements, authorized a share consolidation at a ratio between 1-for-5 and 1-for-30 to be set later by the board, and ratified the appointment of WWC P.C. as independent auditor for the fiscal year ending October 31, 2025.
Park Ha Biological Technology Co., Ltd. filed a Form 6-K related to its 2025 annual general meeting. The company is furnishing a formal notice of the 2025 annual general meeting dated September 12, 2025 and a form of proxy card to be mailed to shareholders. These materials are intended to inform shareholders about the meeting and enable them to vote, either in person or by proxy.
Park Ha Biological Technology Co., Ltd. has received two Nasdaq deficiency notices, one for its share price and one for its market value. Nasdaq notified the company that its ordinary shares failed to meet the minimum closing bid price of $1 per share for 30 consecutive business days, triggering non-compliance with Nasdaq Listing Rule 5550(a)(2). The company has 180 days, until March 2, 2026, to regain compliance by having its bid price at or above $1 for at least ten consecutive trading days.
On the same date, Nasdaq also informed the company that its Market Value of Listed Securities had remained below the required $35 million for 30 consecutive business days under Listing Rule 5550(b)(2). The company has until March 2, 2026 to restore MVLS at or above $35 million for at least ten consecutive business days, or its securities may face delisting, subject to potential additional cure periods and appeal rights. The company states it intends to take reasonable measures and monitor its status but cannot assure it will regain or maintain compliance.
Park Ha Biological Technology Co., Ltd. reported that independent director Mr. Da Yang resigned from the board, effective August 25, 2025. The company states that his resignation was not due to any disagreement with its operations, policies, or procedures, indicating this is presented as a non-controversial board change. The report is signed on behalf of the company by Chief Executive Officer and Chairperson of the Board, Xiaoqiu Zhang.
Park Ha Biological Technology Co., Ltd. (symbol: PHH) filed a Form S-8 on 10 July 2025 to register an additional 4,500,000 ordinary shares for issuance under its Amended and Restated 2025 Share Incentive Plan. The amendment lifts the plan’s total share reserve to 7,500,000 shares, incorporating a prior S-8 filed on 3 March 2025. The filing is strictly administrative, containing standard exhibits such as the legal opinion, the amended plan, auditor consent, and filing-fee table. No financial statements, earnings data, or transaction details are provided; the document’s primary purpose is to facilitate future equity awards to employees, directors, and other eligible participants.